Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:FTFT NASDAQ:INKT NASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.64-9.7%$2.27$1.09▼$3.40$200.96M0.61764,979 shs364,342 shsFTFTFuture FinTech Group$1.07-2.7%$1.30$1.00▼$16.12$6.46M1.7741,089 shs17,786 shsINKTMiNK Therapeutics$11.87-6.9%$11.41$6.80▼$76.00$63.52M0.4744,063 shs51,453 shsSGMTSagimet Biosciences$6.76-4.2%$6.59$4.50▼$11.41$230.05M3.41755,949 shs608,190 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+1.97%-15.81%-29.57%-9.50%+16.77%FTFTFuture FinTech Group0.00%-7.50%-27.45%-23.45%-76.08%INKTMiNK Therapeutics-0.08%+4.51%+10.49%+24.03%+79.58%SGMTSagimet Biosciences+2.92%-2.89%-8.55%+30.50%+73.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.64-9.7%$2.27$1.09▼$3.40$200.96M0.61764,979 shs364,342 shsFTFTFuture FinTech Group$1.07-2.7%$1.30$1.00▼$16.12$6.46M1.7741,089 shs17,786 shsINKTMiNK Therapeutics$11.87-6.9%$11.41$6.80▼$76.00$63.52M0.4744,063 shs51,453 shsSGMTSagimet Biosciences$6.76-4.2%$6.59$4.50▼$11.41$230.05M3.41755,949 shs608,190 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+1.97%-15.81%-29.57%-9.50%+16.77%FTFTFuture FinTech Group0.00%-7.50%-27.45%-23.45%-76.08%INKTMiNK Therapeutics-0.08%+4.51%+10.49%+24.03%+79.58%SGMTSagimet Biosciences+2.92%-2.89%-8.55%+30.50%+73.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$3.63121.71% UpsideFTFTFuture FinTech Group 1.00SellN/AN/AINKTMiNK Therapeutics 2.40Hold$35.00194.86% UpsideSGMTSagimet Biosciences 2.67Moderate Buy$25.75280.92% UpsideCurrent Analyst Ratings BreakdownLatest INKT, FTFT, ALEC, and SGMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026SGMTSagimet Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$35.00 ➝ $12.005/18/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.005/12/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026ALECAlector Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026ALECAlector Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$2.005/4/2026SGMTSagimet Biosciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $49.005/1/2026SGMTSagimet Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/29/2026SGMTSagimet Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $25.004/24/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026SGMTSagimet Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$21.05M8.62N/AN/A$0.28 per share5.84FTFTFuture FinTech Group$3.83M1.64N/AN/A$8.71 per share0.12INKTMiNK TherapeuticsN/AN/AN/AN/A($3.03) per shareN/ASGMTSagimet Biosciences$2M110.12N/AN/A$3.42 per share1.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)FTFTFuture FinTech Group-$4.62M-$3.17N/AN/AN/A-37.76%-13.08%-10.33%N/AINKTMiNK Therapeutics-$12.49M-$2.84N/AN/AN/AN/AN/A-118.57%8/13/2026 (Estimated)SGMTSagimet Biosciences-$51.04M-$1.34N/AN/AN/AN/A-37.57%-35.52%8/12/2026 (Estimated)Latest INKT, FTFT, ALEC, and SGMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026FTFTFuture FinTech GroupN/A-$0.25N/A-$0.25N/A$0.21 million5/15/2026Q1 2026INKTMiNK Therapeutics-$0.77-$0.57+$0.20-$0.57N/AN/A5/12/2026Q1 2026SGMTSagimet Biosciences-$0.39-$0.33+$0.06-$0.33N/AN/A5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million3/18/2026Q4 2025FTFTFuture FinTech GroupN/A$29.81N/A$2.57N/A$1.35 million3/11/2026Q4 2025SGMTSagimet Biosciences-$0.43-$0.29+$0.14-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AFTFTFuture FinTech GroupN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.805.255.25FTFTFuture FinTech GroupN/A6.826.82INKTMiNK TherapeuticsN/A1.381.38SGMTSagimet BiosciencesN/A20.3320.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%FTFTFuture FinTech Group0.19%INKTMiNK Therapeutics2.87%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipALECAlector8.30%FTFTFuture FinTech Group1.50%INKTMiNK Therapeutics22.48%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270111.03 million101.81 millionOptionableFTFTFuture FinTech Group705.87 million5.78 millionNo DataINKTMiNK Therapeutics304.98 million3.86 millionNo DataSGMTSagimet Biosciences832.58 million27.80 millionOptionableINKT, FTFT, ALEC, and SGMT HeadlinesRecent News About These CompaniesHere's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom FisherJune 4 at 10:56 AM | zacks.comSagimet Biosciences Grants New Performance-Based Executive Equity AwardsJune 3 at 6:10 PM | tipranks.comSagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASHMay 27, 2026 | globenewswire.comSagimet Biosciences Inc - Ordinary Shares - Series AMay 21, 2026 | money.usnews.comWall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to TradeMay 21, 2026 | zacks.comSagimet Biosciences (SGMT) price target increased by 15.00% to 29.86May 15, 2026 | msn.comSagimet Biosciences: Making The Bull Case For Differentiated DenifanstatMay 14, 2026 | seekingalpha.comSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 13, 2026 | globenewswire.comSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 12, 2026 | globenewswire.comSagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from JonesTradingMay 11, 2026 | theglobeandmail.comSagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in ChicagoMay 11, 2026 | globenewswire.comSagimet Biosciences (SGMT) Expected to Announce Earnings on ThursdayMay 7, 2026 | marketbeat.comSagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?May 5, 2026 | zacks.comDoes Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?May 5, 2026 | zacks.comSagimet Biosciences stock surges 30% on acne trial plansApril 28, 2026 | au.investing.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 40.04%April 28, 2026 | aaii.comASagimet Biosciences Shares Jump 30% on Acne Trial Expansion PlansApril 28, 2026 | finance.yahoo.comWhy Is Sagimet Biosciences Stock Trading Higher On Monday?April 27, 2026 | benzinga.comSagimet Updates Investor Presentation After Key Clinical MilestonesApril 27, 2026 | tipranks.comSagimet Biosciences Inc. Prices Underwritten Offering of 29.2 Million Shares at $6.00 Each, Expected to Raise $175 MillionApril 27, 2026 | quiverquant.comQSagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common StockApril 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINKT, FTFT, ALEC, and SGMT Company DescriptionsAlector NASDAQ:ALEC$1.64 -0.18 (-9.67%) Closing price 04:00 PM EasternExtended Trading$1.72 +0.08 (+4.89%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Future FinTech Group NASDAQ:FTFT$1.07 -0.03 (-2.73%) As of 04:00 PM EasternFuture FinTech Group Inc., through its subsidiaries, operates online shopping platforms in People's Republic of China. It operates in three segments: Supply Chain Financing Service and Trading Business, Asset Management Service, and Others. The company offers cross-border money transfer service, brokerage and investment banking, and cryptocurrency mining farm business. It also engages in the trading of coal, aluminum ingots, sand, and steel; and E-commerce, digital wallet safety management, blockchain code auditing and operations, cryptocurrency mining, metaverse and big data maintenance services. The company was formerly known as SkyPeople Fruit Juice, Inc. and changed its name to Future FinTech Group Inc. in June 2017. Future FinTech Group Inc. is headquartered in New York, New York.MiNK Therapeutics NASDAQ:INKT$11.87 -0.88 (-6.90%) Closing price 04:00 PM EasternExtended Trading$11.23 -0.64 (-5.39%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Sagimet Biosciences NASDAQ:SGMT$6.76 -0.30 (-4.25%) Closing price 04:00 PM EasternExtended Trading$6.92 +0.16 (+2.29%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
